Le Lézard
Classified in: Covid-19 virus

Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com


The "Growth Opportunities for Digital Biomarkers in Drug Development" report has been added to ResearchAndMarkets.com's offering.

The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact.

Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate.

Digital biomarkers derived from wearable sensors and advanced algorithms offer an opportunity to analyze the response of investigational medical products in clinical trials continuously and remotely. Digital biomarkers eliminate the need for frequent clinic visits to monitor the patient's health status.

The halting of clinical trials because of the COVID-19 pandemic has fueled digital biomarker adoption for remote patient monitoring in clinical practices and clinical trials. Remote patient monitoring is imperative for pharmaceutical companies to conduct efficient clinical trials, save costs, and decide on proceeding with or discontinuing an investigational drug.

Efforts are underway by market participants to transform digital biomarkers into digital measurements or endpoints in clinical trials. Digital biomarkers are instrumental in assessing the efficacy and safety of the therapy in DCTs and timely patient recruitment.

Digital biomarkers offer an opportunity for pharmaceutical companies to advance research in complex diseases, such as AD and PD, and to find novel biomarkers that demonstrate the effectiveness of an investigational drug on a patient's disease condition in clinical trials.

Key Topics Covered:

1. Strategic Imperatives

2. Growth Opportunity Analysis

3. Growth Opportunity Analysis - Neurology

4. Growth Opportunity Analysis - Oncology

5. Regulatory Landscape

6. Industry Assessment and Analysis

7. Patent Landscape

8. Growth Opportunity Universe

For more information about this report visit https://www.researchandmarkets.com/r/izovqq


These press releases may also interest you

at 20:21
Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced the pricing of a public offering of $750 million of 5.625% senior unsecured notes due October 13, 2032 (the "Notes"). The public offering price for the...

at 20:09
In response to a lawsuit filed by Siri & Glimstad LLP on behalf of the Informed Consent Action Network (ICAN), the CDC has released the first set of data from its v-safe program. V-safe is a smartphone-based program created by CDC specifically for...

at 19:45
The "Thermoplastic Composites Market by Fiber Type, Product, End-User, Resin Type, and Geography ? Forecast and Analysis 2022-2026" report has been added to Technavio's offering. According to the report, the market will observe an incremental growth...

at 19:00
The online video platform market will be driven by factors such as the rise in online video consumption. The number of videos watched by online audiences has increased significantly. In addition, there has been a shift in video content from...

at 18:45
Naver Corp. (KRX: 035420) ("Naver"), Korea's largest internet company, and Poshmark, Inc. ("Poshmark"), a leading social e-commerce marketplace for new and secondhand style, today announced that they have entered into a definitive agreement under...

at 18:45
The Medical Device Contract Manufacturing Market size is expected to grow by USD 46.18 bn during 2021-2026, at a CAGR of 11.19% during the forecast period, according to Technavio. The Impact of Industry 4.0 on the medical device industry, strategic...



News published on 16 august 2022 at 12:05 and distributed by: